<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478163</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00051005</org_study_id>
    <nct_id>NCT03478163</nct_id>
  </id_info>
  <brief_title>Antibiotics During Intrauterine Balloon Tamponade Placement</brief_title>
  <official_title>Antibiotics During Intrauterine Balloon Tamponade Placement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to identify whether antibiotics given at the time of placement of
      an intrauterine balloon tamponade (IBT) will result in reduction of the risk of endometritis.
      The investigators hypothesize that antibiotics given at the time of intrauterine balloon
      tamponade will reduce the likelihood of postpartum endometritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will perform a randomized, controlled trial of women who have had a
      postpartum hemorrhage and received an intrauterine balloon tamponade.

      Patients who are candidates for study enrollment will be identified on Labor &amp; Delivery or in
      the Maternal-Fetal Care Unit. Patients who give consent will be randomized by random number
      generator to receive either antibiotics (Group A) or no antibiotics (Group B).

      If the patient is randomized to Group A, she will receive a 24-hour course of antibiotics.
      The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has
      contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or
      severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.

      If the patient is randomized to Group B, she will not receive antibiotics as part of the
      study, though if at any time her provider chooses to administer antibiotics either
      prophylactically or for treatment she will not prohibited in any way from this or any other
      treatment as appropriate.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label, randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postpartum endometritis</measure>
    <time_frame>6 weeks</time_frame>
    <description>Incidence of postpartum endometritis as defined by clinical documentation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fever</measure>
    <time_frame>6 weeks</time_frame>
    <description>Fever &gt; 38 degrees celsius</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound infection</measure>
    <time_frame>6 weeks</time_frame>
    <description>Wound infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound breakdown</measure>
    <time_frame>6 weeks</time_frame>
    <description>Wound breakdown</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receiving postpartum antibiotics</measure>
    <time_frame>6 weeks</time_frame>
    <description>Receiving postpartum antibiotics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hysterectomy</measure>
    <time_frame>6 weeks</time_frame>
    <description>Hysterectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for additional uterotonics</measure>
    <time_frame>2 weeks</time_frame>
    <description>If any of misoprostol, carboprost, or methylergonovine were given after Bakri placement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EBL</measure>
    <time_frame>2 weeks</time_frame>
    <description>Estimated blood loss prior to removal, following removal, and total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum hemoglobin and hemoglobin change</measure>
    <time_frame>2 weeks</time_frame>
    <description>Postpartum hemoglobin and hemoglobin change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>2 weeks</time_frame>
    <description>Blood transfusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal ICU admission</measure>
    <time_frame>6 weeks</time_frame>
    <description>Maternal ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal death</measure>
    <time_frame>6 weeks</time_frame>
    <description>Maternal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource utilization measures</measure>
    <time_frame>6 weeks</time_frame>
    <description>Duration of admission to maternal-fetal care unit and total hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmission</measure>
    <time_frame>6 weeks</time_frame>
    <description>Hospital readmission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Obstetric Complication</condition>
  <condition>Postpartum Hemorrhage</condition>
  <condition>Postpartum Endometritis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patient will not receive antibiotics as part of the study, though if at any time her provider chooses to administer antibiotics either prophylactically or for treatment she will not prohibited in any way from this or any other treatment as appropriate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will receive a 24-hour course of antibiotics. The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CeFAZolin 1000 MG</intervention_name>
    <description>Cefazolin 1000 mg every 8 hours for 3 doses</description>
    <arm_group_label>Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin 900 MG in 6 ML Injection</intervention_name>
    <description>Clindamycin 900 mg every 8 hours for 3 doses</description>
    <arm_group_label>Antibiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Able to give consent

          -  Gestational age &gt; 24 weeks

          -  Postpartum

          -  Placement of an IBT within the last 2 hours with plans for it to remain in situ for at
             least 2 hours

          -  Primary obstetrician amenable to proceeding with either method of management during
             the study period.

        Exclusion Criteria:

          -  Age &lt; 18 years old

          -  IBT removed within 2 hours of placement

          -  Chorioamnionitis

          -  Insufficient documentation of demographics, delivery outcomes, or peripartum events
             including postpartum hemorrhage, infectious outcomes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patient must be postpartum</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Gregory, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa S Wong, MD</last_name>
    <phone>310-423-0895</phone>
    <email>Melissa.Wong2@cshs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kimerly Gregory, MD MPH</last_name>
    <phone>3104230895</phone>
    <email>gregory@cshs.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa S Wong, MD</last_name>
      <phone>310-423-0895</phone>
      <email>Melissa.Wong2@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Gregory, MD MPH</last_name>
      <phone>3104230895</phone>
      <email>gregory@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kimberly D Gregory, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Kimberly Gregory</investigator_full_name>
    <investigator_title>Director, Women's Reproductive Health Services</investigator_title>
  </responsible_party>
  <keyword>Bakri</keyword>
  <keyword>Intrauterine balloon tamponade</keyword>
  <keyword>Antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

